Point72 Europe (London) LLP Biogen Inc. Transaction History
Point72 Europe (London) LLP
- $2.52 Billion
- Q2 2025
A detailed history of Point72 Europe (London) LLP transactions in Biogen Inc. stock. As of the latest transaction made, Point72 Europe (London) LLP holds 95,680 shares of BIIB stock, worth $14 Million. This represents 0.48% of its overall portfolio holdings.
Number of Shares
95,680
Previous 82,476
16.01%
Holding current value
$14 Million
Previous $11.3 Million
6.47%
% of portfolio
0.48%
Previous 0.84%
Shares
2 transactions
Others Institutions Holding BIIB
# of Institutions
1,027Shares Held
131MCall Options Held
2.84MPut Options Held
2.57M-
Vanguard Group Inc Valley Forge, PA17.3MShares$2.53 Billion0.04% of portfolio
-
Primecap Management CO Pasadena, CA15.8MShares$2.31 Billion1.62% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.13 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.47MShares$1.09 Billion0.04% of portfolio
-
Wellington Management Group LLP Boston, MA4.8MShares$702 Million0.11% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $21.1B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...